drugset / Trial / NCT04331899

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

NCT04331899

Phase 2 Completed 120 enrolled Stanford University
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.

Timeline

Start
2020-04-25
Primary completion
2020-08-14
Completion
2021-05-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon Lambda-1a Protein / enzyme biologic 180 ug Subcutaneous

Indications